Stroke and diabetes
The research is focused along two major research lines: The study of the cellular mechanisms at the basis of the neurological complications of diabetes and the identification of efficacious preclinical therapies for the treatment of stroke in diabetes.
Stroke affects several million people worldwide, of which a substantial proportion of cases present in patients suffering from diabetes. Diabetes is widespread and represents the fourth leading cause of death in the U.S. About 97 % of the medical and social costs associated with diabetes are dominated by care for macrovascular complications such as stroke.
The relationship between diabetes and stroke is just beginning to be understood - antidiabetic drugs have been suggested to have a protective effect in stroke patients and ideally new treatment strategies for diabetes could be designed with an offshoot effect of reducing the risk of stroke.
Recent data published by the research group suggest just such a role for the glucagone-like receptor 1 (GLP-1R) agonists. These drugs have been shown to be neuroprotective and to stimulate adult neural stem cells.
Glucagon-like peptide-1 receptor activation reduces ischemic brain damage following stroke in type 2 diabetic rats
Clin Sci (Lond). 2012 May 1;122(10):473-83.
Pituitary adenylate cyclase-activating polypeptide counteracts the impaired adult neural stem cell viability induced by palmitate
J Neurosci Res. 2012 Apr;90(4):759-68. doi: 10.1002/jnr.22803. Epub 2011 Dec 20.
The specific VPAC2 agonist Bay 55-9837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats.
Neuropeptides. 2012 Sep 13. pii: S0143-4179(12)00083-2. doi: 10.1016/j.npep.2012.08.008. [Epub ahead of print]
The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse Brain: A Comparison With Glimepiride.
Diabetes. 2012 Dec 3. [Epub ahead of print]